Head-to-head evidence
JMKX001899 vs Sotorasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
JMKX001899
Developed by Jemincare
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07242274 (registry estimate)
Sotorasib
Marketed by Amgen and partners
NCT04303780 · Phase 3 · completed
The 345 participants were randomized 1:1 to sotorasib or active-comparator docetaxel, but treatment assignment was not masked. The primary clinical endpoint, progression-free survival assessed by blinded independent central review, was met in favor of sotorasib, with median progression-free survival of 5.62 versus 4.47 months and a hazard ratio of 0.663 (p=0.002).
Next expected readout: October 2026 · NCT06333951 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JMKX001899's landscape · Sotorasib's landscape